Industry

Alcon, RxSight to develop light-adjustable presbyopia IOL

Healio Optometry2d ago1 min read

Alcon and RxSight announced a nonexclusive collaboration to develop a light-adjustable presbyopia-correcting IOL, according to a press release.“This collaboration will enable surgeons to fine-tune visual outcomes for their cataract patients who choose a PCIOL, which is not an available option today,” Ron Kurtz, MD, president and CEO of RxSight, told Healio.The collaboration aims to combine RxSight’s postoperative light-adjustable technology with Alcon’s presbyopia-correcting optical designs to create the novel IOL technology. Alcon will pay RxSight $60 million upfront to begin development,

Read full article on Healio Optometry

AI Summary

Quick Take

Alcon and RxSight have entered into a nonexclusive collaboration to develop a first-of-its-kind light-adjustable presbyopia-correcting intraocular lens (PCIOL). The partnership aims to combine Alcon’s advanced optical designs with RxSight’s proprietary postoperative adjustment technology, supported by an initial $60 million payment from Alcon to RxSight.

Why It Matters

This collaboration addresses one of the primary hurdles in premium cataract surgery: the inability to adjust the refractive power of a presbyopia-correcting lens once it is inside the eye. Currently, surgeons must choose between the postoperative precision of the Light Adjustable Lens (LAL) and the multifocality of a PCIOL. By merging these technologies, the industry moves closer to a 'no-compromise' premium lens that can be fine-tuned to a patient's specific visual needs after the eye has healed, potentially reducing the need for secondary laser enhancements and improving patient satisfaction rates.

Key Details

The collaboration is nonexclusive, allowing both Alcon and RxSight to maintain strategic flexibility.
Alcon is providing an upfront payment of $60 million to RxSight to begin the development phase.
The project aims to integrate RxSight’s light-adjustable material with Alcon’s existing presbyopia-correcting optical platforms.
The technology is designed to enable surgeons to fine-tune visual outcomes specifically for cataract patients who choose a PCIOL, an option not currently available in the market.

Practice Implications

If successful, this technology would allow clinicians to offer presbyopia correction to a broader range of patients, including those with previous refractive surgery where IOL calculations are notoriously difficult. Surgeons could focus on the optical performance of the lens during the initial procedure, knowing they have the safety net of postoperative adjustment to eliminate residual refractive errors. This could significantly streamline the counseling process for premium lenses by reducing the risk of a 'refractive surprise.'

Who's Affected

Cataract SurgeonsRefractive SurgeonsComprehensive OphthalmologistsOptometristsPractice Owners

What's Next

Following the $60 million upfront payment, the companies will begin the technical development of the novel IOL. While no specific timeline for clinical trials or regulatory submission was provided, the industry will be watching for updates on whether this new lens will be compatible with existing RxSight Light Delivery Device (LDD) hardware.

AI-generated summary — always read the original source for full context

Discussion

No comments yet. Be the first to share your thoughts.